Pharmaceutical

AMG-305 by Amgen for Breast Cancer: Likelihood of Approval

AMG-305 is under clinical development by Amgen and currently in Phase I for Breast Cancer.

Jul 7, 2023 - 20:00
AMG-305 is under clinical development by Amgen and currently in Phase I for Breast Cancer.
Read the original article

Tags:

Previous Article

STAT+: Novo Nordisk bought prescribers over 450,000 meals and snacks to promote ...

Next Article

ORIN-1001 by Shanghai Fosun Pharmaceutical (Group) for Kidney Cancer (Renal Cell...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Dying patients protest looming telehealth crackdown

Dying patients protest looming telehealth crackdown

Apr 23, 2023

EC expands Takeda’s Adcetris label for advanced Hodgkin lymphoma treatment

EC expands Takeda’s Adcetris label for advanced Hodgkin...

Oct 19, 2023

WHO declares end of Covid-19 public health emergency

WHO declares end of Covid-19 public health emergency

May 6, 2023